

INTERNATIONAL SUMMER SCHOOL ON IMMUNO-ONCOLOGY: EMERGING TARGETS AND COMBINATION THERAPIES

MEETING

Verbania

August 30th – September 2nd 2021

Directors

MARISA GARIGLIO
ALESSANDRA GENNARI
ANTONIO SICA

24 CME POINTS
IN-CLASS COURSE

36 CME POINTS
WEBINAR LIVE

FOR INFORMATION
www.accmed.org

OBJECTIVES

The “Summer School of Immuno-Oncology: Emerging targets and combination therapies” aims to discuss knowledge and recent advances in the field of cancer immunotherapy. A panel of national and international lecturers will cover various aspects of preclinical and clinical immuno-oncology, ranging from the study of basic pathogenetic mechanisms for the discovery of new immunotherapeutic targets to more clinical aspects related to the effectiveness of combinatorial approaches in boosting cancer immunotherapy. The school will provide young oncologists, PhDs and PhD students, involved in clinical and research projects related to cancer immunotherapy, with a solid background in novel immuno-oncology topics. In particular, we will focus on issues related to: inflammation and cancer; the immunity-cancer interface: mutational load of the tumor and editing of immune responses; myelopoietic alterations, tumor microenvironment and anticancer immunotherapy; radioimmunotherapy and immunotherapy of blood cancers; clinical immunotherapy; antiviral response of the host and cancer development; role of immunosenescence and inflammaging in neoplasms; and immunological disorders and cancer. Furthermore, advanced knowledge on statistics will be provided for the analysis of preclinical and clinical data. The goal is to discuss the current state of knowledge in the field of cancer immunotherapy from an interdisciplinary and translational “bench-to-bedside” standpoint.

ADDRESSED TO

Physicians and Resident doctors in oncology, clinical immunology and allergology, hematology, microbiology and virology, radiotherapy; Biologists, Pharmacists, but also PhD students, students and graduates of the degree programme in Pharmaceutical Chemistry and Technology and Biotechnology.

With the patronage of



PROGRAM

Monday, 30th August

- 10.00 *Registration and welcome coffee*
- 10.30 **Opening Address**
Gian Carlo Avanzi, Marco Krengli
- 11.00 **Introduction to the school and programme presentation**
Marisa Gariglio, Alessandra Gennari, Antonio Sica
- 11.30 **Opening Lecture**
Cancer and Inflammation - Alberto Mantovani
Chairmen: Gian Carlo Avanzi, Antonio Sica
- 12.30 *Lunch break*

AFTERNOON SESSION

The cancer-immune system interface

Chairmen: Gianluca Aimaretti, Ciro Isidoro

- 14.00 **Tumor mutational load and cancer therapy**
Giovanni Germano
- 14.45 **Targeting adaptive immunity in cancer**
Enrico Lugli
- 15.30 *Coffee break*
- 16.00 **Professional antigen presenting cells/DC in cancer**
Silvano Sozzani
- 16.45 **Immune checkpoints in cancer therapy**
Andrea Anichini
- 17.30 **Discussion**
Facilitator: Antonio Sica
- 18.00 **Adjourn**

Tuesday, 31st August

MORNING SESSION

Anticancer immunotherapies: pros and cons

Chairmen: Umberto Dianzani, Antonia Follenzi

- 8.40 **Lecture**
Update on anticancer immunotherapies
Paolo Antonio Ascierto
- 9.40 **Extracellular Matrix at the cross-road between cancer and immunity**
Mario Colombo
- 10.00 **Tumor microenvironment and emergency hematopoiesis**
Laura Strauss

10.30 *Coffee Break*
11.00 **Suppressor myeloid cells in cancer**
Vincenzo Bronte

11.30 **NK in cancer therapy**
Angela Santoni

12.00 **Discussion Q&A**
Facilitator: Gianluca Gaidano

12.30 **Giovanni Melillo interviewed by Pier Luigi Canonico (NO CME)**

13.00 *Lunch Break*

AFTERNOON SESSION

Hemato & Radio Immunotherapy

Chairmen: Marco Krengli, Andrea Riccardo Filippi

14.30 **Radiotherapy and immunotherapy:
current knowledge of a clinical partnership**
Pierfrancesco Franco

15.00 **Radiotherapy effects on tumor micro-environment**
Andrea Riccardo Filippi

15.30 **SBRT and immunotherapy, a winning partnership?**
Davide Franceschini

15.50 *Coffee Break*

AFTERNOON SESSION

Hemato & Radio Immunotherapy

Chairmen: Gianluca Gaidano, Giovanni Martinelli

16.20 **Molecular determinants of immune-response**
Massimo Dominici

16.40 **Immune checkpoints inhibitors in liquid tumors**
Gianluca Gaidano

17.10 **CAR-T cells**
Marco Ladetto

17.30 **Discussion Q&A**
Facilitator: Giovanni Martinelli

18.15 **CME Session Adjourn**

18.30 **Cocktail with the statisticians (NO CME)**
Chairmen: Paolo Bruzzi, Fabrizio Faggiano, Giovanni Melillo

Innovative trial design – Adaptive Immunotherapy Trials

Oriana Nanni, Valter Torri (15 min)

Endpoints & Summary Indicators in Immunotherapy Trials

Paolo Bruzzi (15 min)

Wednesday, 1st September

MORNING SESSION

Immunotherapy in the Clinic

Chairmen: Pier Luigi Canonico, Alessandra Gennari

9.00 **Lecture**

Regulatory Process and clinical benefit

Armando Genazzani

09.40 **IO & Lung Cancer**

Silvia Novello

10.00 **IO & Urology**

Matteo Bellone

10.20 **Immunotherapy of Melanoma:**

what we already know and future perspectives

Michele Del Vecchio

10.40 *Coffee Break*

11.00 **Breast Cancer:**

evolution of innovative agents from CDK 4/6 to checkpoint inhibitors

Valentina Guarneri

11.20 **IO & Hepatocellular carcinoma**

David J. Pinato

11.40 **Innovative IO therapies in solid tumors:**

CAR-T, oncolytic viruses and beyond

Giuseppe Curigliano

12.15 **Antiandrogenic therapy in prostate cancer and COVID**

Andrea Alimonti

12.30 **Discussion Q&A**

Facilitator: Alessandra Gennari

13.00 *Lunch Break*

AFTERNOON SESSION

The complex interplay between SARS-CoV-2 and the host immune response

Chairmen: Marisa Gariglio, Santo Landolfo

14.30 **Vaccines and monoclonals to regain our freedom**

Rino Rappuoli

15.10 **SARS COV2 variants**

Nicole Fischer

15.50 **Innate RNA sensing of SARS-CoV2 and strategies of viral evasion**

John Hiscott

16.30 *Coffee Break*

- 17.00 **The cGAS-STING pathway in COVID-19 – protective and pathogenic potential**
Soren Paludan
- 17.40 **Discussion Q&A**
Facilitator: Marco De Andrea
- 18.00 **Adjourn**
-

Thursday, 2nd September

MORNING SESSION

Immunosenescence, Inflammaging and Cancer

Chairmen: Lia Rimondini, Annalisa Chiocchetti

- 9.00 **Inflammaging and Cancer**
Massimiliano Bonafè
- 9.50 **Common mechanisms of age-related diseases: implication for disease-specific biomarkers identification**
Fabiola Olivieri
- 10.40 *Coffee Break*
- 11.10 **Genetics and Epigenetics of Aging**
Paolo Garagnani
- 12.00 **Discussion Q&A**
Facilitator: Ciro Isidoro
- 12.30 *Lunch Break*

AFTERNOON SESSION

Immunological disorders and cancer prognosis and therapy

Chairmen: Claudio Santoro, Mario Pirisi

- 14.00 **Allergy/autoimmunity and cancer**
Marinos Kallikourdis
- 14.50 **Microbioma, immunity and cancer**
Maria Rescigno
- 15.10 **Tertiary lymphoid structures in immunology and immunotherapy**
Catherine Sautès-Fridman
- 15.30 **Discussion Q&A**
Facilitator: Antonio Sica
- 16.00 **Closing Lecture**
B cells and antibodies, the next challenge in immunotherapy
Wolf Fridman
- 16.30 **Adjournment**
Marisa Gariglio, Alessandra Gennari, Antonio Sica

DIRECTORS

Marisa Gariglio

*Dipartimento di Medicina Traslazionale
UPO – Università del Piemonte Orientale
Novara*

Alessandra Gennari

*Divisione di Oncologia
Ospedale Maggiore della Carità
Dipartimento di Medicina Traslazionale
UPO – Università del Piemonte Orientale
Novara*

Antonio Sica

*Dipartimento di Scienze del Farmaco
UPO – Università del Piemonte Orientale
Novara*

CHAIRMEN AND SPEAKERS

Gianluca Aimaretti

*Dept. Translational Medicine
UPO, Novara, IT*

Andrea Alimonti

*Institute of Oncology Research
ETH Zurich, CH*

Andrea Anichini

*Dept. of Research, Fondazione IRCCS
Istituto Nazionale dei Tumori
Milano, IT*

Paolo Antonio Ascierto

*Dept. Medical Oncology and Innovative
Therapy, Fondazione Pascale IRCCS INT
Napoli, IT*

Gian Carlo Avanzi

*Dept. Translational Medicine
UPO, Novara, IT*

Matteo Bellone

*Dept. Immunology, Transplantation
and Infectious Diseases
IRCCS Ospedale San Raffaele
Milano, IT*

Massimiliano Bonafè

*Dept. of Specialized
Diagnostic and Experimental Medicine
University of Bologna, IT*

Vincenzo Bronte

*Dept. of Pathology and Diagnostics
University of Verona, IT*

Paolo Bruzzi

*Epidemiologo
Genova, IT*

Pier Luigi Canonico

*Dept. Pharmacological Sciences
UPO, Novara, IT*

Annalisa Chiocchetti

*Dept. Health Sciences and CAAD
UPO, Novara, IT*

Mario Colombo

*Dept. of Research, Fondazione IRCCS
Istituto Nazionale dei Tumori
Milano, IT*

Giuseppe Curigliano

*Development of New Drugs for Innovative
Therapies
IEO, Milano, IT*

Marco De Andrea

Dept. Sciences of Public Health and Pediatrics, University of Turin, IT

Michele Del Vecchio

Unit of Melanoma Medical Oncology
Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori
Milano, IT

Umberto Dianzani

Department of Health Sciences
UPO, Novara, IT

Massimo Dominici

Dept. of Medical and Surgical Sciences for Children & Adults, Università degli Studi di Modena e Reggio Emilia, IT

Fabrizio Faggiano

Dept. Translational Medicine
UPO, Novara, IT

Andrea Riccardo Filippi

Radiation Oncology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, IT

Nicole Fischer

Universitätsklinikum Hamburg-Eppendorf
Hamburg, DE

Antonia Follenzi

Department of Health Sciences
UPO, Novara, IT

Davide Franceschini

Radiotherapy and Radiosurgery Department
Humanitas Clinical and Research Hospital IRCCS Rozzano (MI), IT

Pierfrancesco Franco

Dept. Translational Medicine
UPO, Novara, IT

Wolf Fridman

Paris Descartes University, F

Gianluca Gaidano

Dept. Translational Medicine
UPO, Novara, IT

Paolo Garagnani

Department of Specialized Diagnostic and Experimental Medicine
University of Bologna, IT

Armando Genazzani

Department of Pharmaceutical Sciences
UPO, Novara, IT

Giovanni Germano

Department of Oncology, University of Turin
Candiolo Cancer Institute, IT

Valentina Guarneri

Unit of Medical Oncology 2, IOV Veneto
Padova, IT

John Hiscott

Istituto Pasteur, Roma, IT

Ciro Isidoro

Dept. of Health Science
UPO, Novara, IT

Marinos Kallikourdis

Department of Biomedical Sciences
Humanitas University and Adaptive Immunity Laboratory
Humanitas Research Hospital
Milano, IT

Marco Krenegli

Dept. Translational Medicine
UPO, Novara, IT

Marco Ladetto

Dept. of Hematology, UPO, Alessandria, IT

Santo Landolfo

Department of Public Health and Pediatrics
University of Turin, IT

Enrico Lugli

Laboratory of Translational Immunology
Humanitas Clinical and Research Center
Rozzano (MI), IT

Alberto Mantovani

Scientific Director
Humanitas Clinical and Research Center
Rozzano (MI), IT

Giovanni Martinelli

Scientific Director, IRST
Meldola (FC), IT

Giovanni Melillo

*Vice President. Immuno-oncology
Global Medical Affairs,
AstraZeneca Oncology
Gaithersburg, Maryland, USA*

Oriana Nanni

*Unit of Biostatistics and Clinical trials
IRST IRCCS, Meldola (FC), IT*

Silvia Novello

*Department of Oncology
University of Turin, IT*

Fabiola Olivieri

*Department of Clinical and Molecular
Sciences, UNIPM, IT*

Soren Paludan

*Department of Biomedicine
Aarhus University, DK*

David J. Pinato

*Faculty of Medicine
Department of Surgery & Cancer
Imperial College, UK*

Mario Pirisi

*Dept Translational Medicine
UPO, Novara, IT*

Rino Rappuoli

*GSK Vaccines, Siena, Italy
MAD Lab (TLS)
Siena, IT*

Maria Rescigno

*Humanitas Clinical and Research Center
IRCCS, Milano, IT*

Lia Rimondini

*Dept. of Health Science
UPO, Novara, IT*

Angela Santoni

*Dept. of Molecular Medicine
University La Sapienza
Roma, IT*

Claudio Santoro

*Dept. Health Sciences and CAAD
UPO, Novara, IT*

Catherine Sautès-Fridman

Paris Descartes University, F

Silvano Sozzani

*Dept. of Molecular Medicine
University La Sapienza
Roma, IT*

Laura Strauss

*EMD Serono Research Center
Billerica, Massachusetts, USA*

Valter Torri

*Laboratory of Methodology for Clinical
Research, Istituto Mario Negri IRCCS
Milano, IT*

ACCESS MODE

To ensure compliance with the health provisions regarding Covid 19, the meeting will be held both as an in-class course and as a live webinar.

The **in-class course** will take place at the venue specified underneath. Please note that due to COVID mitigation measures, Only a limited number of attendees will be accepted.

The **LIVE Webinar** will allow participants to attend the meeting from remote.

When registering, it is necessary to select the desired participation mode (in-class or remote). Registration for the activity can only take place online, no registrations will be accepted at the meeting venue.

Participants who decide to follow the LIVE webinar, will need a good Internet connection and a device (PC, Smartphone, Tablet) capable of running an updated Internet browser (e.g. Chrome or Firefox).

AccMed will organize the event exclusively in digital mode in case of worsening of the current COVID-19 emergency. In this case, AccMed will inform speakers and participants.

The official language of the course is English. No simultaneous translation will be provided.

REGISTRATION

The registration fees are:

€ 300,00 In-class course

€ 200,00 In-class course for UPO Staff & Students

€ 100,00 LIVE Webinar

Online registration at <https://summerschool.accmed.org/> within 20th August; the application will be completed only after the payment of the registration fee.

CANCELLATION

In order to cancel please give advise with a written communication to Accademia Nazionale di Medicina within 10 days from the beginning. A 70% of the registration fee will be returned. Any cancellation after that deadline will not be reimbursed.

CME IN-CLASS COURSE

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (31-325502): **24 CME points.**

Training objective: professional and technical content (knowledge and skills) specific to each profession, specialisation and highly specialised activity. Rare disease.

The credit certification for the webinar is subject to:

- Professions/specializations should correspond to those which have been accredited for CME
- attendance at the 100% of the event
- the completion of the Meeting evaluation online form;
- completion of the final test (at least 75% of correct answers). 1 attempt admitted.

The test and the meeting evaluation form must be completed within 3 days from the end of the event.

CME WEBINAR LIVE

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (31-325681): **36 CME points.**

Training objective: professional and technical content (knowledge and skills) specific to each profession, specialisation and highly specialised activity. Rare disease.

The credit certification for the webinar is subject to:

- Professions/specializations should correspond to those which have been accredited for CME
- attendance at the live webinar on the platform fad.accmed.org;
- the completion of the Meeting evaluation online form;
- completion of the final test (at least 75% of correct answers). 5 attempts admitted.

The test and the meeting evaluation form must be completed within 3 days from the end of the event.

MEETING VENUE

Villa San Remigio
Università del Piemonte Orientale
Via San Remigio 20
28922 Verbania

INFORMATION AND REGISTRATION

segreteriaicorsi@accmed.org
Tel 010 83794238
Fax 010 83794260

PROMOTED BY

Accademia Nazionale di Medicina
www.accmed.org
Direttore Generale Stefania Ledda

LOGISTICS AND TECHNOLOGY

Forum Service
Via Martin Piaggio 17/8
16122 Genova



HOTEL BOOKING

Tel 010 83794243
Fax 010 83794261
booking@forumservice.net

WITH THE UNRESTRICTED SPONSORSHIP OF

MAJOR SPONSOR



SPONSOR

